Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.

MLA

Cyrenne, Benoit M., et al. “Synergy of BCL2 and Histone Deacetylase Inhibition against Leukemic Cells from Cutaneous T-Cell Lymphoma Patients.” Blood, vol. 130, no. 19, Nov. 2017, pp. 2073–83. EBSCOhost, https://doi.org/10.1182/blood-2017-06-792150.

APA

Cyrenne, B. M., Lewis, J. M., Weed, J. G., Carlson, K. R., Mirza, F. N., Foss, F. M., & Girardi, M. (2017). Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood, 130(19), 2073–2083. https://doi.org/10.1182/blood-2017-06-792150

Chicago

Cyrenne, Benoit M, Julia M Lewis, Jason G Weed, Kacie R Carlson, Fatima N Mirza, Francine M Foss, and Michael Girardi. 2017. “Synergy of BCL2 and Histone Deacetylase Inhibition against Leukemic Cells from Cutaneous T-Cell Lymphoma Patients.” Blood 130 (19): 2073–83. doi:10.1182/blood-2017-06-792150.